Feeds

UK drugs trial hospitalises six

Intensive care for 'seriously ill' men

Build a business case: developing custom apps

Six drug trial volunteers who were given an anti-inflammatory drug at a private research unit based at London's Northwick Park Hospital are in intensive care after suffering a "reaction", the BBC reports.

The six were given TGN1412 - "designed to treat conditions such as rheumatoid arthritis and leukaemia" - on Monday. Within hours they were hospitalised after suffering "an inflammatory response which affects some organs of the body", as Northwick's intensive care director Ganesh Suntharalingam put it.

Suntharalingam explained that two of the men were in a critical condition, while the remainder were "serious but showing some signs of improvement".

The girlfriend of one of the men described her 28-year-old boyfriend's face as so swollen he "looks like the Elephant Man". Myfanwy Marshall told the BBC: "His friends cannot even face seeing him. I have to stay there because I'm looking beyond all the wires and the puffiness. This is not leukaemia, this is not pneumonia, this is not something they know how to deal with."

Parexel, the firm behind the trial, said it had followed guidelines and that such cases were extremely rare. The company's Professor Herman Scholtz said: "When the adverse drug reaction occurred, the Parexel clinical pharmacology medical team responded swiftly to stop the study procedures immediately."

The drug's German-based manufacturer, TeGenero, said the reactions were "completely unexpected and did not reflect results from initial laboratory studies".

The Medicines and Healthcare products Regulatory Agency (MHRA), meanwhile, immediately withdrew the trial's authorisation and issued an international warning against testing. Its inspectors have visited the unit and are consulting the local health authority, Department of Health and police with regard to the matter.

According to the BBC, the drug had already been tested on animals and cleared for human trials. ®

Next gen security for virtualised datacentres

More from The Register

next story
Boffins attempt to prove the UNIVERSE IS JUST A HOLOGRAM
Is this the real life? Is this just fantasy?
China building SUPERSONIC SUBMARINE that travels in a BUBBLE
Shanghai to San Fran in two hours would be a trick, though
Our LOHAN spaceplane ballocket Kickstarter climbs through £8000
Through 25 per cent but more is needed: Get your UNIQUE rewards!
CRR-CRRRK, beep, beep: Mars space truck backs out of slippery sand trap
Curiosity finds new drilling target after course correction
SpaceX prototype rocket EXPLODES over Texas. 'Tricky' biz, says Elon Musk
No injuries or near injuries. Flight stayed in designated area
Galileo, Galileo! Galileo, Galileo! Galileo fit to go. Magnifico
I'm just a poor boy, nobody loves me. But at least I can find my way with ESA GPS by 2017
Astronomers scramble for obs on new comet
Amateur gets fifth confirmed discovery
prev story

Whitepapers

A new approach to endpoint data protection
What is the best way to ensure comprehensive visibility, management, and control of information on both company-owned and employee-owned devices?
Implementing global e-invoicing with guaranteed legal certainty
Explaining the role local tax compliance plays in successful supply chain management and e-business and how leading global brands are addressing this.
Maximize storage efficiency across the enterprise
The HP StoreOnce backup solution offers highly flexible, centrally managed, and highly efficient data protection for any enterprise.
How modern custom applications can spur business growth
Learn how to create, deploy and manage custom applications without consuming or expanding the need for scarce, expensive IT resources.
Next gen security for virtualised datacentres
Legacy security solutions are inefficient due to the architectural differences between physical and virtual environments.